Introduction
Cancer ranks as the second leading cause of death, exceeded only by heart disease in the United States.
Each year, about 1.7 million Americans are diagnosed with cancer, and more than a million Americans die of the disease. Cancer develops in almost any organ or tissue of the body, but certain types of cancers are more life threatening than others (Jemal et al., 2009) . Defining the molecular mechanisms linked to the transition from normal to cancer cell is essential for planning strategies in the prevention and/or treatment of cancers. Protein kinase C epsilon (PKCe) and signal transducers and activators of transcription 3 (Stat3) have been shown to have functions in the development of several cancers (Aziz et al., 2007a, b, c) .
STATs are a family of six [Stat1 (a and b isoforms), Stat2, Stat3 (a and b isoforms), Stat4, Stat5 (a, b isoforms), and Stat6)] latent transcription factors, which reside in the cytoplasm and are encoded by seven distinct genes (Klampfer, 2006) . STAT activation is linked to cell proliferation, differentiation, apoptosis, embryogenesis, and immune responses (Nikitakis et al., 2004; Vinkemeier, 2004; Hodge et al., 2005; Kortylewski et al., 2005) . STATs exhibit functional divergence in their functions in oncogenesis. Stat3 and Stat5 promote cell survival, whereas Stat1 has been associated with growth inhibitory effects (Akira, 2000; Stephanou and Latchman, 2005) . Constitutively activated STATs, in particular Stat3, are found in a number of human cancers (for example head and neck, squamous cell carcinoma (SCC), breast, ovary, prostate, and lung) (Chan et al., 2004; Alvarez et al., 2005; Rivat et al., 2005; Kobielak and Fuchs, 2006; Aziz et al., 2007b, c) . As naturally occurring mutations of Stat3 have not been observed, constitutive activation of Stat3 seems to be mediated by aberrant growth factor signaling (Hodge et al., 2005; Klampfer, 2006) . Tyrosine phosphorylation of Stat3 (Tyrosine 705) is mediated by a wide variety of polypeptides and is essential for Stat3 dimerization and nuclear translocation. Stat3 also has a conserved serine727 residue, which is a target for phosphorylation (Decker and Kovarik, 2000) . Evidence indicates that cooperation of both tyrosine and serine phosphorylation is necessary for full activation of Stat3 (Li and Shaw, 2004) .
PKC is a major intracellular receptor for the mouse skin tumor promoter TPA (Kazanietz, 2000) . PKC represents a large family of phosphatidylserine (PS)-dependent serine/threonine kinases (Mellor and Parker, 1998; Mochly-Rosen and Kauvar, 1998; Newton, 2001; Griner and Kazanietz, 2007) . On the basis of structural similarities and co-factor dependency, 11 PKC isoforms have been classified into 3 subfamilies: classical (cPKC), novel (nPKC), and atypical (aPKC) isoforms. The cPKCs (a, bI, bII, and g) are dependent on PS, diacylglycerol (DAG), and Ca 2 þ . The nPKCs (d, e, Z, and y) retain responsiveness to DAG and PS, but do not require Ca 2 þ for full activation. The aPKCs (l and B) only require PS for their activation (MochlyRosen and Kauvar, 1998) . PKC isoforms exhibit functional specificity in their signals to oncogenesis (Griner and Kazanietz, 2007) . PKCe participates in the regulation of diverse cellular functions including gene expression, neoplastic transformation, cell adhesion, mitogenicity, and cellular motility. Overexpression of PKCe in rodent fibroblasts leads to increase in growth rates, anchorage independence, and tumor formation in nude mice (reviewed in Basu and Sivaprasad, 2007) . PKCe has been shown to be a transforming oncogene (Basu and Sivaprasad, 2007) , and a predictive biomarker of various human cancers (Pan et al., 2005) , including prostate cancer (PCa) (Wu et al., 2002) . We found PKCe is linked to the development of SCC (Reddig et al., 2000; Jansen et al., 2001; Wheeler et al., 2003 Wheeler et al., , 2004 Wheeler et al., , 2005 . PKCe is also overexpressed in human PCa (Cornford et al., 1999) . Overexpression of PKCe transforms androgen-dependent LNCaP tumor cells to an androgenindependent variant (Wu et al., 2002) . The transformation of androgen-dependent to an androgen-independent variant was associated with increased cell proliferation and resistance to apoptosis (Wu et al., 2004) .
We have shown that PKCe interacts with Stat3, phosphorylates Stat3Ser727, and increases both DNA binding and transcriptional activity of Stat3 in skin (Aziz et al., 2007b, c) and PCa (Aziz et al., 2007a) . However, it is unknown whether association of PKCe with Stat3 is universal. We present novel results in this communication that (1) PKCe interacts with Stat3 and phosphorylates Stat3Ser727 in various human cancer cells: skin melanoma (MeWo and WM266-4), glioma (T98G and MO59K), bladder (RT-4 and UM-UC-3), colon (Caco-2), lung (H1650), pancreatic (PANC-1), and breast (MCF-7 and MDA:MB-231); (2) inhibition of PKCe expression, using PKCe-specific siRNA, inhibits Stat3Ser727 phosphorylation, Stat3-DNA binding, Stat3-regulated gene expression as well as cell invasion not only in PCa, but also in several others cancer cell lines including melanoma, glioma, pancreas and lung; and (3) PKCe may integrate with MAPK cascade (Raf-1, MEK1/2, and ERK1/2) to phosphorylate Stat3Ser727.
Results

PKCe and Stat3 interaction in various human cancer cell lines
Various human cancer cell lines were used to test the hypothesis that the association of PKCe with Stat3 is universal. The interaction of PKCe with Stat3 in glioma (T98G and MO59K) and breast (MCF-7, MDA:MB-231) cancer cell lines is shown in Figure 1 . T98G is a glioblastoma mutiformae fibroblast cell and not tumorigenic in nude mice, whereas M059K is a malignant gliomblastoma fibroblast and forms tumors in SCID mice. Expression levels of PKCe and Stat3 in T98G and M059K are shown in Figure 1ai . The basal levels of PKCe expression were higher (32%) in M059K compared with T98G cells. Stat3 has two conserved amino-acid (Tyr705 and Ser727) residues, which are phosphorylated during Stat3 activation. PKCe only interacts with Stat3a isoform, which has Ser727, and not with Stat3b isoform, which lacks Ser727. In addition, MO59K elicited a high level of pStat3Tyr705a (53%), pStat3Tyr705b (537%), and pStat3Ser727 (64%) as compared with T98G cells (Figure 1bi ). PKCe and Stat3 interaction in estrogen-dependent MCF-7 human breast cancer cells and estrogen-independent MDA:MB-231 human breast cancer cells is also shown in Figure 1 . MDA:MB-231, as compared with MCF-7, exhibited high expression levels of PKCe (63%) pStat3Tyr705 (225%) and pStat3Ser727 (255%) (Figures 1aii and bii) . Reciprocal immunoprecipitation (IP)/blotting experiments indicate that PKCe physically interacts with Stat3 in glioblastoma and breast cell lines (Figure 1ci and ii). As shown in Figure 1ciii , the inclusion of blocking peptide in the IP experiments inhibited the interaction of PKCe with Stat3, providing straightforward evidence for the protein-protein interactions of PKCe and Stat3. Each IP experiment included a control that contained no primary antibody, but pre-immune rabbit serum. Neither PKCe nor Stat3 was pulled down with the preimmune serum. Furthermore, the IP experiments were repeated with both polyclonal and monoclonal antibodies and polyclonal antibody from different commercial suppliers. Irrespective of the source of the antibody, the results were identical. The co-localization of PKCe with Stat3 was confirmed by double immunofluorscence staining (Figure 1d ). Merge images (yellow fluorescence) indicate localization of both PKCe and Stat3 in cytoplasm and nucleus.
The interaction of PKCe with Stat3 in human melanoma (MeWo and WM266-4), lung adenocarcinoma cell lines (H1650), colon adenocarcinoma Caco2 cells, pancreatic carcinoma (PANC-1), and bladder cancer cells (RT-4, UM-UC-3) is illustrated in Figure 2 . WM266-4 is an aggressive metastatic melanoma cell line, whereas MeWo is a non-metastatic melanoma cell line. As compared with MeWo, WM266-4 cells elicited higher expression levels of PKCe (161%), pStat3Tyr705a (195%), pStat3Tyr705b (133%), and pStat3Ser727 (167%) (Figures 2a and bi) . Similarly, merge images depict significant localization of PKCe and Stat3 in metastatic melanoma cell lines WM266-4 ( Figure 2di 
Functional consequence of PKCe interaction with Stat3
To determine that PKCe-mediated Stat3Ser727 phosphorylation is essential for Stat3 DNA binding, Stat3-regulated gene expression, and cell invasion, we used PKCe-specific siRNA to silence PKCe in melonoma (WM266-4), glioma (T98G), pancreatic (PANC-1), and lung (H1650) cancer cells. In this experiment (Figure 3 ), PKCe-specific siRNA was transfected in all the cancer cells to inhibit PKCe expression. Silencing of PKCe using PKCe siRNA resulted in significant inhibition of PKCe without inhibition of expression of other PKC isoforms such as PKCd and PKCa (Figure 3a) .
Inhibition of PKCe attenuated Stat3Ser727 phosphorylation, but not Stat3Tyr705 phosphorylation (Figure 3b ). Inhibition of PKCe-mediated Stat3Ser727 phosphorylation ( Figure 3b ) accompanied inhibition of Stat3-DNA binding (data not shown) and Stat3-regulated gene expression (Figure 3c ). The results indicate that inhibition of PKCe results in suppression of both Stat3Ser727 phosphorylation and Stat3-regulated gene expression. However, the effects are indeed cell-type specific. Silencing of PKCe significantly (Po0.01) inhibited cell invasion in melonoma (WM266-4), glioma (T98G), pancreatic (PANC-1), and lung (H1650) cancer cells.
PKCe-mediated Stat3Ser727 phosphorylation involves integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2) The results (Figures 1-3) presented clearly indicate that PKCe interacts with Stat3. However, it is unknown whether PKCe interacts with other protein kinase cascade to phosphorylate Stat3Ser727. To explore the possibility that PKCe-Stat3 interaction is mediated through other protein kinases, we used PCa from transgenic adenocarcinoma of mouse prostate (TRAMP) mice and DU145 cells. In reciprocal IP/ blotting experiments, using PCa from TRAMP mice, Raf-1, MEK-1/2, and ERK1/2 co-immunoprecipitated with PKCe and Stat3 (Figure 4a ).
To further determine whether PKCe mediates Stat3-Ser727 phosphorylation through activation of MAPK cascades (Raf-1, MEK1/2, and ERK1/2), we used siRNAs to silence PKCe in DU145 cells (Figure 4b ). The transfection was performed as per the manufacturer's instructions (Dharmacon Inc., Lafayette, CO, USA). A pool of four specific siRNA oligonucleotides directed against PKCe was transfected into DU-145 cells to inhibit PKCe synthesis and non-targeting siRNA was used as a control (Figure 4b ). Inhibition of PKCe (93%) Figure 3 PKCe mediates phosphorylation of Stat3Ser727, Stat3-regulated genes expression, and cell invasion in human cancer cells. Melanoma (WM266-4), glioma (T98G), pancreatic (PANC-1), and lung (H1650) cancer cells were transfected with 15 mg of nontargeting siRNA plasmid (lane 1) or PKCe-specific siRNA plasmid (lane 2) (Ambion) for 48 h and whole-cell lysates were prepared as described in Materials and methods. The whole-cell lysates (25 mg protein) were immunoblotted and indicated protein expression levels were detected with appropriate antibodies. b-actin was used as a control for gel loading variations. Protein quantification (normalized to b-actin) was performed as described in Materials and methods (right side). Expression levels of: (a) (i, ii) PKC isoforms (PKCe, PKCd, and PKCa), (b) (i, ii) pStat3Ser727, pStat3Tyr705, Stat3, and (c) (i, ii) Stat3-regulated genes (Bcl-xL, and COX-2). (d) Human cancer cell invasion. Cells were transfected with non-targeting siRNA plasmid or PKCe-specific siRNA plasmid (Ambion) and cell invasion was determined as described in Materials and methods. (ii) Photographs of invading cells. The migrant cells were stained with crystal violet and photographed the invading cells ( Â 40 magnification); (iii) number of invading cells was estimated by colorimetric measurements at 560 nm according to assay instructions (Chemicon International, Temecula, CA, USA). Each value in the graph is the mean ± s.e. from three separate wells.
in DU145 cells using PKCe-specific siRNA inhibited the phosphorylation of Raf-1Ser338 (55%), pMEK1/2 (38%), pERK1 (53%), pERK2 (58%), and COX-2 (59%) without affecting total Raf-1, MEK1/2, and ERK1/2 levels (Figures 4c and e) . In a separate experiment (Figure 5 ), silencing of ERK1/2 using ERK1/2-specific siRNA inhibited PKCe-mediated Stat3Ser727 phosphorylation. Taken together, the results indicate that PKCe may integrate with MAPK cascade to phosphorylate Stat3Ser727.
Discussion
PKCe, a Ca 2 þ -independent phospholipid-dependent PKC, is linked to cancer induction, progression, and metastasis (Basu and Sivaprasad, 2007; Griner and Kazanietz, 2007) . PKCe is constitutively activated in various human cancers and PKCe levels correlate with aggressiveness of human cancers including breast (Pan et al., 2005) , HNSCC (Pan et al., 2006) , prostate (Aziz et al., 2007a) , lung (Bae et al., 2007) , brain (Okhrimenko et al., 2005) , and SCC (Aziz et al., 2007b, c) . In addition, when PKCe is over expressed, it transforms rat fibroblasts, colonic epithelial cells, and androgen-dependent LNCaP cells to an androgen-independent variant (Wu et al., 2002) . Constitutively activated PKCe regulates the activation of signaling networks linked to cell survival (Basu and Sivaprasad, 2007) . We have earlier reported both in skin (Aziz et al., 2007b, c) and prostate (Aziz et al., 2007a) cancer that PKCe may mediate inhibition of apoptosis and promotion of survival of neoplastic cells through its association with Stat3, a transcription factor that is constitutively activated in various human cancers (Chan et 1 and 2) or PKCe-specific siRNA (lanes 3 and 4) (Dharmacon Inc.), and whole-cell lysates were prepared as described before (Figure 3 ). The lysates (25 mg protein) were immunoblotted and indicated protein expression levels were detected with the appropriate antibodies. b-actin was used as a control for gel loading variations. Protein quantification (normalized to b-actin) was performed as described in Materials and methods. Each value is the mean ± s.e. of three independent experiments. (d) Electrophoretic mobility shift assay. DU145 total cells were suspended in buffer A [10 mmol/l HEPES (pH 7.9), 1.5 mmol/l MagCl 2 , 10 mmol/l KCl, 0.5 mmol/l DTT, 0.2 mmol/l PMSF]. After 15 min of incubation on ice, the cells were pelleted and resuspended in buffer B [20 mmol/l HEPES (pH 7.9), 20 mmol/l NaF, 1.5 mmol/l MgCl 2 , 1 mmol/l Na 3 VO 4 , 1 mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l DTT, 0.5 mmol/l PMSF, 420 mmol/l NaCl, 20% glycerol, 1 mg/ml leupeptin, 1 mg/ml aprotinin]. The samples were then centrifuged and the clear supernatant was used for electrophoretic mobility shift assay as described in Materials and methods. Lane 1, free probe only; lane 2, non-targeting; lane 3, PKCe siRNA; and lane 4, mutant probe.
Stat3, phosphorylates Stat3Ser727, and regulates both Stat3-DNA binding and transcriptional activity (Aziz et al., 2007a, c) . Now, we present that PKCe regulates Stat3Ser727 phosphorylation, not only in skin and prostate, but also in several cancer cell lines: skin melanomas (MeWo and WM266-4), glioma (T98G and MO59K), bladder (RT-4 and UM-UC-3), colon (Caco-2), lung (H1650), pancreatic (PANC-1), and breast (MCF-7 and MDA:MB-231). PKCe integrates with MAPK cascade to phosphorylate Stat3Ser727 (Figures 4 and  5) . PKCe-mediated Stat3Ser727 phosphorylation is essential for cancer cell invasion (Figure 3d) .
PKCe is overexpressed and constitutively activated in various human cancers (for example glioma, melanoma, breast, prostate) (Wu et al., 2002 (Wu et al., , 2004 Okhrimenko et al., 2005; Pan et al., 2005; Aziz et al., 2007a, c) . The present results with various human cancer cell lines further support the evidence for increased expression levels of PKCe in cancer (Figure 1-3) . The mechanism linked to increased PKCe protein stability in cancer is not defined. The signaling lifetime of PKC is under the control of multiple mechanisms . PKC is synthesized in the cytoplasm as an inactive precursor. A series of ordered phosphorylation converts PKC into a mature stable species. Binding to lipid second messenger controls the propagation of PKC signals. Termination of PKC signaling is achieved by mechanisms, which include dephosphorylation and proteolytic degradation and degradation of fully phosphorylated PKC by the ubiquitin-proteosome pathway . Several studies indicate that PKC isozymes become ubiquitinated after activation. PKCa, d, and e have been reported to become ubiquitinated after treatment of cells with phorbol esters or another potent PKC agonist, bryostatin. Both proteasome-sensitive and -insensitive pathways have been proposed to regulate PKC degradation. The specific machinery controlling the degradation of unprocessed or activated PKC remains to be elucidated. Chen et al. (2007) from Dr Alexandra C Newton's laboratory discovered the function of novel E3 ubiquitin ligase in ubiquitination and degradation of PKC isozymes. Increased PKCe expression level in aggressive cancers may be the result of increased PKCe synthesis and/or decreased degradation. Decreased degradation may be the result of either decreased expression of E3 ligase (RINCK1) or/and lack of recognition of PKCe by E3 ligase. Many RING domain proteins, such as MDM2, C-Chol, and a BRCA1, have intrinsic E3 ligase activities and regulate cellular proteins. It is also notable that breast cancerassociated gene-2 (BCA2), a novel RING domain protein, has E3 ubiquitin ligase activity and correlates with the outcome in invasive breast cancer (Burger et al., 2005 (Burger et al., , 2006 .
The novel finding is the observation that PKCe is an initial signal that regulates human cancer cell invasion (Figure 3d ). This is accomplished through phosphorylation of Stat3Ser727. The experiments involving use of PKCe-specific siRNA provide unequivocal evidence that PKCe-mediated Stat3Ser727 phosphorylation is the important event in the constitutive activation of Stat3, Stat3-DNA binding, and Stat3-regulated gene expression.
PKCe is linked to the induction and progression of human cancers (Griner and Kazanietz, 2007; Aziz et al., 2007a, c) . PKCe accomplishes its oncogenic function through mediation of anti-apoptotic and pro-survival signals (Basu and Sivaprasad, 2007; Griner and Kazanietz, 2007) . We were the first to discover that PKCe signals oncogenic activity through activation of Stat3 (Aziz et al., 2007a, b) . Stat3 is a protein partner of PKCe. Stat3 is constitutively activated in human cancers. PKCe interacts with Stat3 to phosphorylate Stat3Ser727, which is essential for Stat3 transcription activity and cell invasion. The results of reciprocal/IP blotting experiments (Figures 1 and 2) clearly illustrate that PKCe physically interacts with Stat3. PKCe-Stat3 interaction was observed in various human cancer cell lines, implying that PKCe activation may be an initial signal in the constitutive activation of Stat3 in wide variety of human cancers.
Depending on the cellular context, Stat3 has been shown to be a substrate for several protein kinases (Jain et al., 1999) . Stat3 has been shown to be an in vitro substrate for MAP kinase and/or ERKs, which raises the possibility that Stat3 integrates signals from MAP kinases. Members of the MAPK and JNK families of serine kinases may mediate serine 727 phosphorylation (Xuan et al., 2005) . Pioneering research from Dr Zigang Dong's laboratory shows that UV-induced Ser727 phosphorylation in both Stat1 and Stat3 involves the integration of multiple kinase pathways (Zhang et al., 2001 (Zhang et al., , 2003 Zykova et al., 2005) . Our results indicate, using PKCe RNA interference experiments, that PKCemediated Stat3Ser727 phosphorylation involves integration of the MAPK cascade (Raf-1, MEK1/2, and ERK1/2) (Figures 4a-c) .
In summary, PKCe activation is an initial signal in the constitutive activation of Stat3 that is observed in a wide variety of human cancer cells (Figures 1-3 ). PKCe integrates with MAPK cascade to phosphorylate Stat3-Ser727 (Figures 4 and 5) . PKCe-mediated Stat3Ser727 phosphorylation is essential for constitutive activation of Stat3 (Figure 3) . PKCe is constitutively activated in human cancers (Figures 1 and 2 ) and is linked to cancer invasion (Figure 3) . We conclude that PKCe is an initial signal, which directs its partner Stat3 to maintain the invasive cancer. PKCe and Stat3 are potential targets for human cancer prevention and treatment.
Materials and methods
Materials
The antibodies and their sources used in this study were PKCe, Stat3, pStat3Tyr705, Bcl-xL, COX-2, b-actin, donkey anti-goat immunoglobulin-FITC for PKCe, donkey antirabbit immunoglobulin-rhodamine for Stat3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and pStat3Ser727 (BD Biosciences, San Jose, CA, USA). Double-stranded Stat3 consensus DNA-binding motif 5 0 -GATCCTTCTGGGAATT CCTAGATC-3 0 was obtained from Santa Cruz Biotechnology. PKCe-siRNA and siRNA transfection reagents were purchased from Dharmacon Inc. PKCe-siRNA plasmid was purchased from Ambion, Austin, TX, USA. ERK1/2 siRNA, non-targeting siRNA and transfection reagent were purchased from Santa Cruz Biotechnology. Collagen-Based Cell Invasion Assay kit was from Millipore, Temecula, CA, USA.
Cell lines
Various human cancer cell lines, such as skin melanoma (MeWo and WM266-4), glioma (T98G and MO59K), bladder (RT-4), colon (Caco-2), lung (H1650), pancreatic (PANC-1), and breast (MCF-7 and MDA:MB-231), were obtained from ATCC (Manassas, VA, USA). Cancer cell lines were cultured as follows: skin melanomas (MeWo and WM266-4) were grown in MEM containing 10% fetal bovine serum and 1% penicillin-streptomycin; gliomas T98G was grown in MEM containing 10% fetal bovine serum and 1% penicillinstreptomycin, and MO59K was grown in a 50:50 solution of DMEM and Ham's F12 containing 15 mmol/l HEPES, 10% fetal bovine serum, and 1% penicillin-streptomycin; bladder RT4 cell line was grown in McCoy's 5a medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, and UM-UC-3 was grown in MEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. Colon Caco-2 cell line was grown in MEM containing 20% fetal bovine serum and 1% penicillin-streptomycin; lungs H1650 cell line was grown in RPMI-1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin); pancreatic PANC-1 cell line was grown in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin; and breast MCF-7 cells were grown in MEM containing 0,01% bovine insulin, 10% fetal bovine serum and 1% penicillin-streptomycin, and MDA:MB-231 cells were grown in Leibovitz's L-15 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. All the cells were incubated at 5% carbon dioxide, 37 1C except MDA:MB-231, which was incubated at 37 1C without carbon dioxide .
Western blot analysis Indicated human cancer cells were lysed in IP lysis buffer (50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES, pH 7.5], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride [PMSF] , 200 mM Na 3 VO 4 , 200 mM NaF, and 1 mM EGTA). The homogenate was centrifuged at 14 000 g for 30 min at 4 1C. A total of 25 mg of whole-cell lysate was fractionated on 10-15% Tris-glycine SDS-polyacrylamide gels for western blot analysis as described before (Aziz et al., 2007a, c) .
Determination of PKCe and Stat3 localization by double immunofluorescence staining Formalin-fixed human cancer cells were used to determine the localization of PKCe and Stat3 as described before (Aziz et al., 2007a, c) .
Transfection
Cells were transiently transfected with PKCe-siRNA (2 mmol/l/ 100-mm Petri dish), PKCe-siRNA plasmid (15 mg/dish) as per the manufacturer's instruction (Dharmacon Inc.). For ERK1/ 2 siRNA transfection, DU-145 cells were serum starved for 24 h before transfection. Cells were transiently transfected with (120 nmol of ERK1 siRNA þ 120 nmol ERK2 siRNA) or 240 nmol of non-targeting siRNA and were harvested 48 h post-transfection. Whole-cell lysates were made and 25 mg of protein was subjected for western blot analysis.
Cell invasion assay
Cell invasion was assayed using a Collagen-Based Cell Invasion Assay kit as per the manufacturer's instructions (Millipore). Briefly, WM266-4 (melanoma), PANC-1 (pancreatic), Caco-2 (colon), and H1650 (lung) cancer cells at 80% confluency were serum starved 18-24 h before the assay. The cells were harvested and the pellets were gently resuspended in serum-free medium. In the upper chamber, 0.5 Â 10 6 cells per well were plated in triplicates and incubated for 2 h at 37 1C in a humidified incubator with 5% carbon dioxide before PKCespecific siRNA plasmid transfection. Both the insert and the holding well were subjected to the same medium composition with the exception of serum. The insert contained no serum, whereas the lower well contained 10% fetal bovine serum that served as a chemoattractant. A total of 15 mg of PKCe-specific siRNA plasmid was then transfected into the cells. An equal amount of non-targeting siRNA plasmid was used as a control (Ambion). Forty-eight hours after siRNA transfection, the cell invasion assay was carried out as per the manufacturer's instructions. The cells in the insert were removed by wiping gently with a cotton swab. Migrated cells sticking to the bottom side of the insert were stained with cell stain. Invading cells on the bottom side of the membrane were photographed using a light inverted microscopy (Nikon Eclipse TS 100) at Â 40 magnification. In addition, the number of cells migrated to the bottom side was estimated by colorimetric measurements at 560 nm. Mean ± s.e. was calculated from three independent experiments.
Electrophoretic mobility shift assay Nuclear protein extracts from the indicated cells were prepared by lysing cells in a hypotonic solution (10 mM HEPES, pH 7.5; 10 mM KCl; 0.1 mM EDTA, pH 8.0; 0.1 mM EGTA pH 8.0; 1 mM DTT; 0.5 mM PMSF; 0.5 mg/ml benzamide; 2 mg/ml aprotinin; 2 mg/ml leupeptin), with detergent (NP-40 at 6.25% (v/v)) followed by low speed (1500 g for 30 s) to collect nuclei. Nuclear proteins were extracted in a high-salt buffer (20 mM HEPES, pH 7.5; .4 M NaCl; 1 mM EDTA, pH 8.0; 1 mM EGTA pH 8.0; 1 mM DTT; 1 mM PMSF; 0.5 mg/ml benzamide; 2 mg/ ml aprotinin; 2 mg/ml leupeptin) and incubated on ice for 15 min; nuclear membranes and genomic DNA removed by high-speed (16 000 g) centrifugation at 4 1C for 5 min. The nuclear protein extract was incubated in a final volume of 20 ml of 10 mM HEPES (pH 7.9), 80 mM NaCl, 10% glycerol, 1 mM DTT, 1 mM EDTA, and 100 mg/ml poly(deoxyinosinic-deoxycytidylic acid) for 15 min. g-p
32
-radiolabeled double-stranded oligonucleotides of the consensus binding sequences of Stat3 were then added and the complexes were incubated for 20 min at room temperature. The protein-DNA complexes were resolved on a 4.5% acrylamide gel containing, 2.5% glycerol, and 0.5 Â Tris-borate EDTA at room temperature. Gels were dried and autoradiographed to determine binding activity (Aziz et al., 2007a) .
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